Table 3.
Comparison analysis from whole genome gene expression profile showing genes that are upmodulated and downmodulated in NB-CSCs (SM-CSC-L, SM-CSC-L-CD133+, vs. SM-CSC-L-CD34+) compared with non-CSC tumor cells (SH-SY5Y); in designated CSCs (SM-CSC-L-CD133+, vs. SM-CSC-L-CD34+) compared with unsorted NB-CSCs (SM-CSC-L; and in CD133+CD34+ (SM-CSC-L-CD34+) CSCs compared with CD133+CD34− (SM-CSC-L-CD133+) CSCs. Outcomes of the crisscross analysis are presented in overall, significant (≥2 fold), and highly significant (≥10 fold) settings. CSCs = Cancer Stem Cells; NB = Neuroblastoma
| Group | Comparisons | Total | Overall Up | ≥2 Fold Up | ≥10 Fold Up | Overall Down | ≥2 Fold Down | ≥10 Fold Down |
|---|---|---|---|---|---|---|---|---|
| A | SH-SY5Y vs. SM-CSC-L | 50,737 | 30,131 | 3,255 | 270 | 20,468 | 3,142 | 249 |
| B | SH-SY5Y vs. SM-CSC-L-CD133+ | 50,737 | 29,778 | 2,905 | 164 | 20,821 | 3,391 | 214 |
| C | SH-SY5Y vs. SM-CSC-L-CD34+ | 50,737 | 30,127 | 4,902 | 406 | 20,472 | 5,082 | 738 |
| D | SM-CSC-L vs. SM-CSC-L-CD133+ | 50,737 | 20,133 | 2,215 | 72 | 29,466 | 2,818 | 70 |
| E | SM-CSC-L vs. SM-CSC-L-CD34+ | 50,737 | 22,016 | 4,846 | 290 | 28,583 | 5,314 | 659 |
| F | SM-CSC-L-CD133+ vs. SM-CSC-L-CD34+ | 50,737 | 22,715 | 4,631 | 274 | 27,884 | 4,678 | 572 |
| Common Up | Magnified | Reverted to Up | Common Down | Magnified | Reverted to Down | |||
| G | A vs. B (only ≥10 Fold) | 163 | 56 | 1 | 196 | 145 | 18 | |
| H | A vs. C (only ≥10 Fold) | 366 | 317 | 40 | 542 | 711 | 196 | |
| Overall Up | ≥2 Fold Up | ≥10 Fold Up | Overall Down | ≥2 Fold Down | ≥10 Fold Down | |||
| I | D vs. E (Common) | 14,271 | 1,152 | 49 | 21,721 | 1,060 | 4 |